Adalimumab: real life efficacy in rheumatoid arthritis

New data from the ongoing ReAct study (Research in Active Rheumatoid Arthritis) confirm the efficacy and tolerability of adalimumab [Humira] observed in previous large clinical trials of the drug. ReAct, the largest clinical study of an anti-TNF-α agent ever conducted in Europe, collected 'real life' data from > 2000 patients with active rheumatoid arthritis (RA) who had not experienced an adequate response to DMARDs. The study, along with important data about the sustained benefits of adalimumab beyond 5 years and its ability to inhibit radiographic progression, was reported recently at the European League Against Rheumatism (EULAR) congress [Berlin, Germany; June 2004].